Key Takeaways
- • OliX Pharmaceuticals raised approximately KRW 110 billion ($72.7–$73.4 million) through a third-party share allotment, with newly issued shares priced at KRW 149,599 each, representing a 10% discount to the reference price of KRW 166,221.
- • The investment was jointly led by BOLD, L'Oréal's corporate venture capital fund, and Weiss Asset Management LP, a U.S.-based asset manager that previously invested in OliX in August 2025, signaling repeat institutional confidence in the platform.
- • OliX intends to deploy capital to advance siRNA-based therapeutic projects in skin and hair-related applications, leveraging its RNA interference platform while strengthening its strategic partnership with L'Oréal's innovation ecosystem.
- • The equity participation by BOLD underscores L'Oréal's commitment to combining OliX's siRNA platform capabilities with the cosmetics conglomerate's century-long expertise in beauty innovation, biology, tech, and formulation science.
Summary
OliX Pharmaceuticals, a South Korean developer of RNA interference (RNAi) therapeutics trading on KOSDAQ under ticker 226950, announced on June 4, 2026, that it has successfully raised approximately KRW 110 billion through a third-party share allotment. The investment was jointly executed by BOLD, the corporate venture capital arm of L'Oréal, and Weiss Asset Management LP, a U.S. asset management firm. The newly issued common shares were priced at KRW 149,599 per share, reflecting a 10% discount to the reference price of KRW 166,221, with BOLD receiving 70,367 shares as part of the capital raise.
The dual investor structure reflects both strategic and financial confidence in OliX's technology platform. Weiss Asset Management, which participated in an earlier investment round in August 2025, returned as an investor in this round, demonstrating sustained conviction in the company's clinical and commercial trajectory. BOLD's participation marks a significant expansion of L'Oréal's commitment to OliX, transitioning from partnership to direct equity ownership. According to Guive Balooch, Global Managing Director of Open Innovation and Augmented Beauty at L'Oréal, the investment strengthens the strategic collaboration between the two entities, positioning OliX's siRNA capabilities within L'Oréal's broader ecosystem of beauty innovation and biotechnology expertise.
OliX plans to allocate the newly secured capital toward advancing its siRNA-based therapeutic pipeline, with particular focus on skin and hair-related applications—areas of clear strategic alignment with L'Oréal's core beauty and wellness business. The company expects the investment to reinforce its research foundation, accelerate development progress, and deepen its partnership with L'Oréal's innovation infrastructure. The capital raise underscores the growing institutional interest in RNAi therapeutics as a modality for dermatological and cosmetic applications, with L'Oréal's involvement signaling confidence that OliX's platform can deliver commercially viable solutions in the beauty-biotech intersection.
The dual investor structure reflects both strategic and financial confidence in OliX's technology platform. Weiss Asset Management, which participated in an earlier investment round in August 2025, returned as an investor in this round, demonstrating sustained conviction in the company's clinical and commercial trajectory. BOLD's participation marks a significant expansion of L'Oréal's commitment to OliX, transitioning from partnership to direct equity ownership. According to Guive Balooch, Global Managing Director of Open Innovation and Augmented Beauty at L'Oréal, the investment strengthens the strategic collaboration between the two entities, positioning OliX's siRNA capabilities within L'Oréal's broader ecosystem of beauty innovation and biotechnology expertise.
OliX plans to allocate the newly secured capital toward advancing its siRNA-based therapeutic pipeline, with particular focus on skin and hair-related applications—areas of clear strategic alignment with L'Oréal's core beauty and wellness business. The company expects the investment to reinforce its research foundation, accelerate development progress, and deepen its partnership with L'Oréal's innovation infrastructure. The capital raise underscores the growing institutional interest in RNAi therapeutics as a modality for dermatological and cosmetic applications, with L'Oréal's involvement signaling confidence that OliX's platform can deliver commercially viable solutions in the beauty-biotech intersection.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.